Clinical trial NCT05931575: Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease
Official title: Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease (ROCK-PD)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Idiopathic Parkinson´s Disease
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2023-07-05
Enrollment: 75
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this phase Ila trial is to provide evidence on safety, tolerability and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with early Parkinson's disease (PD). Fasudil has shown neuroprotective and pro-regenerative effects, modulated microglial activity and attenuated alpha-synuclein aggregation in PD models in vitro and in vivo. It has been licensed in Japan since 1995 for the treatment of vasospasms and has a beneficial safety profile arguing for its repurposing. Up to 15 trial centers in Germany will recruit patients. Blinded trial medication will be prepared and shipped by the University Pharmacy Leipzig. Fasudil in two dosages or placebo will be administered orally twice daily to 75 early PD patients for a total of 3 weeks. Safety, tolerability and symptomatic efficacy endpoints will be assessed up to 4 weeks after end of treatment. Its well-known safety profile and the lack of disease-modifying treatments for PD justifies its use in patients with early Parkinson's disease. ROCK-PD is a prerequisite for subsequent long-term clinical trials assessing disease-modification in PD in addition to symptomatic efficacy.


Eligibility criteria: Inclusion Criteria:

1. Patients with a diagnosis of at least probable PD according to MDS criteria (Postuma et al. MovDis 2015) and
2. Hoehn \& Yahr stage 1 - 3
3. must be non-fluctuating (no wearing-off, no dyskinesia) and stable on symptomatic PD medication for at least 6 weeks
4. age: 30 - 80 years
5. Women of childbearing potential must be non-lactating and surgically sterile or using a highly effective method of birth control and have a negative pregnancy test. Acceptable methods of birth control with a low failure rate (i.e. less than 1% per year) when used consistently and correct are for example implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomized partner
6. Capable of thoroughly understanding all information given and giving full informed consent according to GCP

Exclusion Criteria:

1. Atypical, secondary Parkinsonian syndromes, PD mimics, or any other medical condition known to have an association with Parkinsonian syndromes, which might confound or obscure the diagnosis of PD
2. Patients with a history of intracranial bleeding, known intracerebral aneurysms or Moyamoya disease, or positive family history for the above. If only family history positive, MR- or x-ray-based cranial imaging not older than 24 months must confirm absence of bleeding, aneurysms, or Moyamoya
3. Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment
4. Patients with known arterial hypotension (resting blood pressure \<90/60 mmHg) or previous hypotensive episodes or requiring treatment for increasing of blood pressure, such as fludrocortisone, midodrine, etilefrine, cafedrine, or theodrenaline
5. Patients with an uncontrollable or unstable arterial hypertensive disease (resting blood pressure \>180 mmHg systolic and/or \>120 mmHg diastolic under current antihypertensive medication)
6. Known pulmonary hypertension and any medication prescribed for treatment of pulmonary hypertension
7. Confirmed hepatic insufficiency or abnormal liver function (stable ASAT and/or ALAT greater than 3 times the upper limit of the normal range) and determined to be non-transient through repeat testing
8. Renal insufficiency with a glomerular filtration rate (GFR) \<60 ml/min/1,73m² (calculated by MDRD equation or byCKD-EPI equation) and determined to be non-transient through repeat testing
9. Major psychiatric disorder, significant cognitive impairment or clinically evident dementia precluding evaluation of symptoms
10. Hypersensitivity to any component of the IMP
11. Liable to be not cooperative or comply with the trial requirements (as assessed by the investigator), or unable to be reached in the case of emergency
12. Pregnant or breast-feeding females or females with childbearing potential, if no adequate contraceptive measures are used
13. Previous participation in another clinical study involving trial medication within the preceding 12 weeks or five terminal half times of the longest to be eliminated trial medications (whichever is longer) or previous participation in this trial

Primary outcomes:
measure: Combined occurrence of intolerance and/or occurrence of self-reported and pre-defined treatment-related SAEs
timeFrame: from day 1 to day 22
Secondary outcomes:
measure: Occurrence of intolerance
timeFrame: from day 1 to day 22
measure: Occurrence of self-reported and pre-defined treatment-related SAEs
timeFrame: from day 1 to day 22, and day 1 to day 50
measure: Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
timeFrame: part I and II from day 1 to day 22, and day 1 to day 50; time frame: part III and IV from day 1 to day 10, day 1 to day 22, and day 1 to day 50
measure: MDS-Unified PD Rating Scale (MDS-UPDRS) score
timeFrame: from day 1 to day 22, and day 1 to day 50
measure: Parkinson's Disease Questionnaire (PDQ-8)
timeFrame: from day 1 to day 22, and day 1 to day 50
measure: Non-Motor Symptom Questionnaire (NMSQuest)
timeFrame: from day 1 to day 10, day 1 to day 22, and day 1 to day 50
measure: Montreal Cognitive Assessment (MoCA)
timeFrame: from day 1 to day 22, and day 1 to day 50
measure: Beck's Depression Inventory II (BDI-II)
timeFrame: from day 1 to day 22, and day 1 to day 50
measure: Clinician Global Impression of Improvement (CGI-I) and Patient Global Impression of Improvement (PGI-I)
timeFrame: at day 10, 22 and day 50
Other outcomes:
Locations:
city: Munich
country: Germany
facility: Technische Universität München, Klinikum rechts der Isar, Klinik und Poliklinik für Neurologie
Study officials:
affiliation: Technische Universität München, Klinikum rechts der Isar, Klinik und Poliklinik für Neurologie
name: Paul Lingor, MD
role: PRINCIPAL_INVESTIGATOR
References: